Loss to follow-up during tuberculosis treatment and 5-year mortality in Brazil: A target trial emulation

BACKGROUND: Loss to follow-up (LTFU) during tuberculosis treatment is a major programmatic gap, but how much excess mortality it causes has been difficult to estimate, because individuals who disengage differ from those who do not, and they must survive long enough to be recorded as having disengaged. Quantifying this excess and identifying which populations are at greatest risk are critical to informing program design and resource allocation. METHODS AND FINDINGS: We followed 171,048 people aged 15 years or older starting a first course of tuberculosis treatment in São Paulo State, Brazil, between 2013 and 2023, linking surveillance and mortality registries; 20,830 (12.2%) were LTFU, defined as interruption of treatment for at least 30 consecutive days. Among those LTFU, 65% had received directly observed therapy (DOT). Using a clone-censor-weight target trial emulation, we contrasted two strategies over 60 months from the first day of treatment: disengagement at any point during the first 6 months and remaining in care throughout. Analyses were adjusted for age, sex, race, education, HIV status, diabetes, alcohol use, drug use, incarceration, homelessness, hospitalization at diagnosis, clinical form of tuberculosis, DOT, and municipality. A rolling landmark analysis addressed the timing of disengagement and cause-specific mortality excess. LTFU increased standardized 5-year mortality by 2.49 percentage points (95% CI [1.94, 3.17]). In a rolling landmark analysis, tuberculosis accounted for 61% of the 5-year excess mortality. Relative effects were largest in younger, stably housed individuals, whose baseline mortality was low; the largest absolute excess fell on people living with HIV (5.16 percentage points, 95% CI [3.76, 6.60]). The excess was similar for disengagement at any point in the first 4 months of treatment and attenuated thereafter. Limitations include the absence from the registry of severity markers such as radiographic extent and bacillary load, so residual confounding cannot be excluded. CONCLUSIONS: Despite high DOT coverage, disengagement during the first 6 months of tuberculosis treatment was common and increased 5-year mortality under the stated identification assumptions, with the excess concentrated in deaths attributed to tuberculosis. Interventions that provide support throughout treatment should be tested for their effectiveness in sustaining engagement and reducing mortality.

Authors

Institutions

Publication Details

Journal
PLoS Medicine
Published
2026-11-18
DOI
https://doi.org/10.1371/journal.pmed.1005303
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Loss to follow-up during tuberculosis treatment and 5-year mortality in Brazil: A target trial emulation

Otávio T. Ranzani, Evelyn Lepka de Lima, Giovanna Mariah Orlandi, Jason Randolph Andrews et al.
2 links
PLoS Medicine
Tuberculosis Research and Epidemiology
article

Loss to follow-up during tuberculosis treatment and 5-year mortality in Brazil: A target trial emulation

Otávio T. Ranzani, Evelyn Lepka de Lima, Giovanna Mariah Orlandi, Jason Randolph Andrews, Ana Angélica Bulcão Portela Lindoso, Júlio Croda, Charles Robert Horsburgh, Suely Fukasava, Meredith B. Brooks, Catia Martinez
article en

Abstract

BACKGROUND: Loss to follow-up (LTFU) during tuberculosis treatment is a major programmatic gap, but how much excess mortality it causes has been difficult to estimate, because individuals who disengage differ from those who do not, and they must survive long enough to be recorded as having disengaged. Quantifying this excess and identifying which populations are at greatest risk are critical to informing program design and resource allocation. METHODS AND FINDINGS: We followed 171,048 people aged 15 years or older starting a first course of tuberculosis treatment in São Paulo State, Brazil, between 2013 and 2023, linking surveillance and mortality registries; 20,830 (12.2%) were LTFU, defined as interruption of treatment for at least 30 consecutive days. Among those LTFU, 65% had received directly observed therapy (DOT). Using a clone-censor-weight target trial emulation, we contrasted two strategies over 60 months from the first day of treatment: disengagement at any point during the first 6 months and remaining in care throughout. Analyses were adjusted for age, sex, race, education, HIV status, diabetes, alcohol use, drug use, incarceration, homelessness, hospitalization at diagnosis, clinical form of tuberculosis, DOT, and municipality. A rolling landmark analysis addressed the timing of disengagement and cause-specific mortality excess. LTFU increased standardized 5-year mortality by 2.49 percentage points (95% CI [1.94, 3.17]). In a rolling landmark analysis, tuberculosis accounted for 61% of the 5-year excess mortality. Relative effects were largest in younger, stably housed individuals, whose baseline mortality was low; the largest absolute excess fell on people living with HIV (5.16 percentage points, 95% CI [3.76, 6.60]). The excess was similar for disengagement at any point in the first 4 months of treatment and attenuated thereafter. Limitations include the absence from the registry of severity markers such as radiographic extent and bacillary load, so residual confounding cannot be excluded. CONCLUSIONS: Despite high DOT coverage, disengagement during the first 6 months of tuberculosis treatment was common and increased 5-year mortality under the stated identification assumptions, with the excess concentrated in deaths attributed to tuberculosis. Interventions that provide support throughout treatment should be tested for their effectiveness in sustaining engagement and reducing mortality.

PLoS MedicineVol. 23(11)
Boston University (US), Universidade Federal de Mato Grosso do Sul (BR), Yale University (US), Instituto de Infectologia Emílio Ribas (BR), Stanford Medicine (US), Institut de Recerca Sant Pau (ES), Fundação Oswaldo Cruz (BR), Stanford University (US)
Good health and well-being
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon